CD79A and dengue disease: Variable results were obtained for COVID-19 Ab EIA platforms [16,46]: a study from Colombia did not observe any cross-reactivity among 23 pre-pandemic serum samples from patients with acute or recent dengue infection [16], whereas for another EIA platform, 22% cross-reactivity was observed among 95 pre-pandemic serum samples of dengue-infected travelers with the Euroimmun IgA/IgG EIA assay [46].